Related Experiment Video
Updated: Jan 13, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
CCR 20th Anniversary Commentary: Vorinostat-Gateway to Epigenetic Therapy
Wm Kevin Kelly1, Paul Marks2, Victoria M Richon3
1Division of Solid Tumor Oncology, Departments of Medical Oncology and Urology, Sidney Kimmel Cancer Center at Thomas Jefferson University. wm.kevin.kelly@jefferson.edu.
Abstract:
The study by Kelly and colleagues, published in the September 1, 2003, issue of Clinical Cancer Research, established the safety and biologic activity of the first-in-class histone deacetylase inhibitor, vorinostat, which was administered intravenously. Subsequent studies led to the development of oral vorinostat and the regulatory approval of vorinostat for cutaneous T-cell lymphomas, which opened the door for the next generation of inhibitors.
More Related Videos
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
Treatment Resistant Cancers
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...